FAVUS ELLIOT 4
4 · ANAVEX LIFE SCIENCES CORP. · Filed Feb 26, 2021
Insider Transaction Report
Form 4
FAVUS ELLIOT
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-24$2.58/sh+45,500$117,390→ 45,000 total - Exercise/Conversion
Common Stock
2021-02-24$3.28/sh+100,000$328,000→ 145,000 total - Sale
Common Stock
2021-02-24$12.66/sh−145,500$1,841,855→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-24−45,500→ 0 totalExercise: $2.58Exp: 2028-10-01→ Common Stock (45,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-24−100,000→ 0 totalExercise: $3.28From: 2016-09-22Exp: 2026-09-22→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The options vested upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.